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Mechanism of Cardiac Resynchronization 
Therapy in the Failing Heart
?????????????????????????????????????????????????????-
duction delay, resulting in dyssynchronous left ventricu-
lar activation, impaired left ventricular systolic function, 
?????????????????????????????????????????????????????????
output (1). An electrical conduction delay is manifes-
ted either as a left bundle branch block (LBBB), right 
bundle branch block (RBBB), or as an intraventricular 
conduction delay (IVCD). Electrical activation of the 
??????????? ????????????????????????????????????????
??????????????????????????????????????????????????????????
LBBB typically have multiple right ventricular (RV) bre-
akthrough sites in the septum as compared to RBBB 
????? ?? ??????? ??? ????????????? ?????? ???????????? ????-
vation time, activation time of the RV, and total activa-
??????? ?? ???????????????? ??????? ????????????????????
??? ?????? ??? ?????????????? ????? ??? ?????? ?????? ??? ??
????? ????? ???????????? ??????????????????????????? ????? ????
septal or anterior breakthrough sites to the apical and 
lateral regions. Most typically, the postero-lateral basal 
region is the latest activated LV area in both LBBB and 
RBBB, providing the rationale for biventricular pacing 
????????????????????????????????????????????????????????????
????????????????????????????????????????????????????
conduction tissue disease than LBBB that is often less 
amenable to CRT.
Cardiac resynchronization therapy (CRT) or biventricu-
???????????????????????????????????????????????????????-
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tor system that delivers electrical stimuli to the right atri-
um, right ventricle, and left ventricle to synchronize the 
????????????????????????????????????????????????????-
tion tissue disease and a severely reduced LV function.
??????????????????????????????????????????????????????
and ventricular contraction in the failing heart and cor-
????????????????????????????????????????????????????????-
ricular dyssynchrony and intraventricular dyssynchrony. 
Atrioventricular dyssynchrony, or PR-prolongation is 
??????????????? ??????????????? ??????? ??????????????????
outcomes (3). The pathophysiology of a prolonged-PR 
interval is primarily based on the atrial systole (A) oc-
curring early in diastole and therefore, it is superimpo-
??????? ?????????? ??????????????????????????????????????-
sequently leading to the fusion of the diastolic E and A 
????????????????????????????????????????????????? ???????
decreasing cardiac output. The early atrial systole un-
couples the mitral valve closure from LV systole resul-
ting in diastolic pre-systolic mitral regurgitation, dec-
?????????????????????????????????????????????????????
???????? ???????????????????????????????? ???? ??????-
tion, normalization of the PR-interval restores the phy-
siologic AV-sequence, eliminating the pathologic E and 
A fusion, and diastolic pre-systolic mitral regurgitation.
Restoration of interventricular and intraventricular 
dyssynchrony via synchronized left ventricular (LV) and 
right ventricular (RV) pacing, or most often, LV pre-ex-
citation additionally results in an immediate decrease 
of intra- and interventricular dyssynchrony, a decrea-
se in mitral regurgitation, and an increase in LV cont-
ractility (4). Long-term CRT use is linked to a reduction 
in LV end-diastolic (LVEDV) and LV end-systolic volu-
me (LVESV), and improvement in LV ejection fraction 
(LVEF), described as LV reverse remodeling (5, 6) (Fi-
gure 1). Eliminating LV dyssynchrony, reducing LV vo-
lumes, and increasing LVEF is the hallmark of cardiac 
?????????????????? ???????? ????? ??? ???????????????? ??-
??????????????????????????????(Figure 2).
Randomized Clinical Trials in Cardiac  
Resynchronization Therapy
There have been a large number of randomized cont-
??????????????????????????????????????????????????????????
of CRT or CRT-D to improve quality of life, HF symp-
toms, functional capacity, and clinical outcomes. These 
???????? ???? ??????????? ?????? ??? Table 1. As it has 
been evidenced in the early studies enrolling 50-100 
?????????? ? ?????????????????? ????????? ????? ???????????
improvement in HF symptoms, functional capacity, and 
??????????? ????? ????????????????????????????????????-
????? ?????? ?????? ????????? ???????? ????????? ???? ??
?????????? ???? ????????? ????????? ???? ???????? ????
????? ????????????? ??????????? ??????????? ???????????
?????????????????????????????????????????????????????
?????????????????????????????????????????????????????-
????? ????????? ? ?????????????????????? ????????????
??????? ??????? ???????? ??? ?????? ?????????????? ?????? ????
also reduces left ventricular volumes, and improves 
?????????????????????????????????????????????????? ?????-
ments in clinical symptoms.
????????????????????????????????????????????????????-
ge clinical trials, Cardiac Resynchronization-Heart Fa-
ilure (CARE-HF), and Comparison of Medical Therapy, 
??????????? ???????????????? ????? ???????????????????
??????????????????????????? ?????????????????? ???????
????????????????????? ????????????? ?????????????????
FIGURE 1. Electrical activation of the left and right ventricle in patients with right bundle branch block and left bundle branch 
block (2)
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????????????????????????????????????????????????????
????????? ????????????? ???? ????????????????? ?????? ???-
dies provided the basis for current guideline-based in-
????????????????????????????????????????????????????





mortality due to progressive HF (13).
?????????? ???? ???????? ??? ???? ??? ???????????? ????-
ents, subsequent clinical trials focused on broadening 
?????????????????? ??????????????? ???? ???? ??????? ??-
???????????????????????????????? ??????????????????????-
diac Resynchronization Therapy (MADIT-CRT), the 
???????????????????????????????? ??? ??????????? ??????
Failure Trial (RAFT) and Resynchronization Reverses 
Remodeling in Systolic Left Ventricular Dysfunction 
?????????????????????????????????????? ????????????????
????????????????????????????????????????????????????
????? ????? ?????? ???????? ????? ?????? ?? ??????????? ??-
duction in HF events and improvement in clinical sy-
?????????????????????????????????????????????????????




in mortality (16, 17).




als, nearly one third of the patients demonstrate a lack 
of echocardiographic or clinical response to CRT, they 
are so-called non-responders. Non-response has been 
the major focus of CRT research the past 25 years to 
optimize use, delivery, and care of CRT patients to opti-
mize outcomes. Non-response to CRT is multifactorial, 
including baseline clinical charcteristics linked to unfa-
vorable outcomes through CRT delivery, and post-imp-
lant factors, such as arrhythmias and CRT program-
ming.
Baseline Clinical Characteristics
There have been a number of clinical factors associ-
?????????????????????????????????????????????????????-
betes, renal dysfunction, and ischemic cardiomyopathy 
(18). On the contrary, a superior response to CRT is 
predicted by female sex, non-ischemic etiology of car-
?????????????????????????????????????????????????????
a less dilated left ventricle (19). The amount of scar has 
????? ?????? ??? ??????????? ??????????????? ????????? ???
????????? ????? ???? ???? ???????? ???????? ???????????????
It is plau sible that advanced scar formation might not 
be amenable to CRT and on the contrary, might be 
arrhyth mogenic, especially if LV pacing occurs near a 
????? ??????? ??? ?????? ??? ????????? ????????? ??????????
??????? ??????????? ?????????????????????? ??? ???????
???????????????????????????????????????????????????????
cardiomyopathy and LBBB, a substrate that is the most 
responsive to biventricular pacing (20).
???????????????????????????????
???????????????????????????????????????????? ??????
????????? ????????????????????? ???? ??????????????????
???????????????????????????????????????? ?????????????
and by the underlying ECG pattern at baseline, befo-
FIGURE 2. Electrical activation of the left and right ventricle in patients with right bundle branch block and left bundle branch 
block (2)
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??????? ? ????????????????????? ?????? ??????????? ???????
????????? ??? ????????? ???? ?????? ??? ???? ??? ??????????
mortality, Cardiac Resynchronization-Heart Failure 





???? ?????? ????????? ???????? ??? ???????????? ??? ????????
response by QRS morphology.




sub-study from MADIT-CRT suggested potential harm 
?????? ??????????? ???????? ????????? ??? ????????????
?????????????????????????????????? ??? ?????????-
???????????????????????????????????????????????????????-
???? ?? ????? ???????????????????????????? ?????????
???? ????????? ??? ?????? ???? ??? ??????? ??? ?????????
????????? ?????? ?? ??????? ??? ?? ?????? ????? ??????????? ??-
gistry, the National Cardiovascular Database Registry 
(NCDR) ICD Registry (25). Based on these observa-




??????????? ????????????????? ????????? ???????????????-
tion for a QRS duration of 120 to 149 ms (26).
The previously conducted and published ECHO-CRT 




complex, unless they require frequent ventricular pa-
??????????????????????????????????????????????????????????
the BLOCK-HF study (29).
?????????????????????
A prolonged PR-interval may result in atrioventricular 
?????????????? ????? ???????? ???????????? ????? ????????????
???????????????????????????????????????????????????????
ces as discussed above (3), and it could potentialy-
ly be another important determinant of CRT response. 
????????????????????????? ?????????????????? ??????-
???????? ?????? ????? ??? ????????? ????? ????????? ????
TABLE 1. Randomized Past and *Ongoing Controlled Trials of Cardiac Resynchronization Therapy. Abbreviations: 6MWT, 6-min 
walk test; CARE-HF, Cardiac Resynchronization-Heart Failure; COMPANION, Comparison of Medical Therapy, Pacing and Defib-
rillation in Heart Failure; HF, heart failure; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular 
ejection fraction; LVESV, left ventricular end-systolic volume; MADITCRT, Multicenter Automatic Defibrillator Implantation Trial–
Cardiac Resynchronization Therapy; MIRACLE, Multicenter InSync Randomized Clinical Evaluation; MIRACLE ICD, Multicenter 
InSync Implantable Cardioverter Defibrillator trial; MR, mitral regurgitation; MUSTIC, Multisite Simulation in Cardiomyopathies; 
NYHA, New York Heart Association; PATH-CHF, Pacing Therapies in Congestive Heart Failure trial; QOL, quality-of-life score; 
RAFT, Resynchronization-Defibrillation for Ambulatory Heart Failure; REVERSE, Resynchronization Reverses Remodeling in Systo-
lic Left Ventricular Dysfunction; VO2, volume of oxygen
Clinical Trial Patients (n) Primary end points Secondary end points LVEF (%) QRS (ms)
MUSTIC-SR 58 6MWT NYHA, QOL, Peak VO2, MR, LV, 
Hosp, Mortality
???? 174
MUSTIC-AF 64 6MWT NYHA, QOL, Peak VO2, Hosp, 
Mortality
???? 206





86 6MWT, peak VO2 NHYA class, QOL,  
Hospitalizations
???? 175
MIRACLE 453 6MWT, NHYA, QOL Peak VO2, LVEF, LVEDD, MR, 
Clin Response
???? 166
COMPANION 1520 All-cause mortality or  
hospitalization
All-cause mortality and cardiac 
mortality
21 159
CARE-HF 814 All-cause mortality NYHA, QOL, LVEF, LVESV,  
Hospitalization for heart failure
25 160
REVERSE 610 HF clinical composite score LVESVi ???? 153
MADIT-CRT 1820 HF or death LVESV, LVEDV change, multiple 
HF events
???? 162
RAFT 1798 All-cause mortality or HF 
hospitalization
All-cause mortality, cardiac  
mortality, HF hospitalization
???? 158
RAFT AF* 412 HF hospitalization or death Mortality, HF hosp, QoL, 6MWT, n.a. n.a.
BUDAPEST CRT 
Upgrade*
360 HF hospitalization, death, or 
lack of LV remodeling
Mortality, HF hospitalization n.a. n.a.
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?????? ??????????????????????? ????????? ?????????-
longed PR-interval in more advanced HF patients (32), 
???? ??? ??????????? ?? ???????????????????? ???????????
?????? ?????????????? ??????? ???????? ??????????? ??????
??????????????????? ??????????????????????????????-
??????? ????? ??????? ??????? ?????????????? ?????? ????????
studies are needed in this cohort.




???????????? ??? ????? ??????? ??????????? ????????? ?????
?????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
the 1990’s reported an improvement in HF symptoms 
????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
??????????? ??? ????????? ????? ?? ?????????? ????? ????????-
lar duntion. In this population, upgrading the pacing or 
ICD device to CRT could potentially improve outcomes. 





control group (38). A large, randomized controlled cli-
nical trial, the BUDAPEST CRT Upgrade study is cur-
??????????????? ?????????????????????????? ??????????????
CRT upgrade from conventional PM or ICD therapy in 
??????????????????????????????????????????????????????????
(RV) septal/apical pacing, reduced LVEF, and sympto-






ry composite endpoint is all-cause mortality, or a HF 
???????????????????????????????????????????????????????-
lume at 12 months (Table 2). Secondary endpoints are 
all-cause mortality, all-cause mortality or HF event, and 




????????? ???????? ??? ????????? ???????????? ?? ??????????
???????????????????????????? ?????????????????????
vs. a CRT-P device. There have been no studies directly 
?????????????????????????????????????????????????-
??????????????????????????????????????????????? ????????
????????? ???????????????? ?????? ????? ?????? ???????
???????????????????????????????????????????????????????-
?????? ???? ??????? ??????????? ??? ???????? ???????????
??????????????????????? ??????????????????????????????
of an added defibrillator (39). In addition, defibrilla-
???????????????????????????????????????????????????????-
tions, lead fractures, and infections. Currently, CRT-P 
???????????????????????????????????????????????????-
???????? ?????????????????????????????????????????????????
high volume registry data additionally suggested that 
????????? ????????????? ??????????????????????? ??????
?????????????????????????????????? ? ????????????????
??????????????????????? ????????? ?????????????? ???-
???????????????????????????? ??????????????????????????
outcomes of CRT-D vs. CRT-P in a randomized fashion 
in both ischemic and non-ischemic patients.
???????????????????????????????????????
???????????
Several previous studies highlighted the importance of 
LV lead location for CRT outcomes. Early studies sug-
gested that lateral or posterolateral LV lead location 
??????????????????????????????????????????????????????
MADIT-CRT and REVERSE highlighted the importan-
ce of avoiding apical LV lead locations to reduce the 
risk of HF or death (42). A subsequent analysis also 
suggested that anterior LV lead placement is linked to 
an increased risk of ventricular arrhythmias and should 
be avoided (43). Several attempts have been made to 
individually optimize LV lead placement and target the 
???????????????????????????????????? ???????????????????
???????????????????????????????????????????????????????
these techniques are currently employed in routine cli-
nical practice. A recent study focusing on CRT non-res-
ponder non-LBBB patients to optimize lead placement 
using LV electrical delay measured by Q-LV, also failed 
to meet its primary end point (https://clinicaltrials.gov/
??????????????????????? ?????? ?????????? ???????-
????????????????????????????????????????? ????????????-
cing, and individually optimized pacing sequences are 
currently studied to further improve outcomes of CRT 
non-responders.
???? ????????????????????????????????????????????-
????? ???? ?????????? ????? ???????? ???????? ???????????
that the higher the biventricular pacing percentage is, 
????????????????????????????????????????????????????????
?????????????????????????????????????????????? ???????
survival in MADIT-CRT. Prior studies assessing optimal 
CRT programming and outcomes using echocardiog-
raphy optimization vs. “out of the box” device settings 
CH_2019_2.indd   85 2019. 05. 20.   12:29:08
86
Cardiologia Hungarica Kutyifa: Cardiac Resynchronization Therapy
???????????????? ?????????????????????????????????-
ver unsuccessful in de novo CRT recipients (47–49), 
??????????????????????????? ???????????????????????
Atrial Fibrillation
??? ????????? ????? ??????? ???????????? ????? ????? ?????? ???
??????????????????????????????? ????????????????????
recipients, lack of biventricular pacing and abrogation of 
the remodeling process are of particular concern. Many 
??????????? ????????? ??????? ????? ????????? ????????? ?????
???????????????????????????? ????????????? ????????????? ?? ?-
ting our understanding of CRT outcomes in this cohort. 
A currently ongoing randomized clinical trial, RAFT-AF 
????????????????????????????????????????????????????????-
???????? ???? ????????????????????????????????????????? ???-
lation and LA substrate ablation vs. rate control in CRT 
recipients, hopefully shedding more lights on treatment 
??????????????????? ??????????????????????????????????
Another prospective, randomized clinical trial of 80 pa-
tients, JAVA-CRT is assessing the role of AV-junctional 
?????????????????????????????????????????????????????????-
lation to improve outcomes (https://clinicaltrials.gov/ct2/
??????????????????
Conclusions
Cardiac resynchronization therapy has evolved as a 
??????????? ???????? ???? ?????? ???????? ??? ????????? ?????
mild to advanced heart failure symptoms, severely de-
???????? ????? ???????????? ????????? ?????????? ???? ?? ?????
QRS. Short- and long-term outcomes have been favo-
???????????????????? ?????????????????????????????????-
racteristics, and comorbidities. Tailored LV lead implan-
tation or CRT programming does not further improve 
????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
RV apical/septal pacing, rhythm control/AV junctional 
????????? ??? ?????????????? ??????? ????????????? ???? ???? ??-
propriate use of CRT-D vs. CRT-P are currently unre-
solved issues that need further investigation to optimize 
outcomes.
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